Biotechnology
Manufacturing
Health
Biogen
$217.509876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$217.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.79 (0.36%) Today
+$0.79 (0.36%) Today
Why Robinhood?
You can buy or sell Biogen and other stocks, options, ETFs, and crypto commission-free!
About
Biogen Inc. Common Stock, also called Biogen, is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Read More It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Employees
7,800
Headquarters
Cambridge, Massachusetts
Founded
1978
Market Cap
42.74B
Price-Earnings Ratio
10.07
Dividend Yield
0.00
Average Volume
1.60M
High Today
$221.27
Low Today
$217.19
Open Price
$220.21
Volume
709.44K
52 Week High
$388.67
52 Week Low
$216.49
Collections
Biotechnology
Manufacturing
Health
Therapy
Technology
US
North America
News
Yahoo Finance35m
Biogen announces $5 billion buyback days after shelving Alzheimer's trials
(Reuters) - Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.
Price Paid on Robinhood
6% Lower
Right Now
52 Week Low
$216.49
Average Price Paid
$231.79
52 Week High
$388.67
Earnings
$4.52
$5.48
$6.44
$7.40
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Available Apr 24, Pre-Market